Appendix: The National Institutes of Health Consensus Development Conference: Management of Hepatitis C 2002
Section snippets
Management of hepatitis C 2002: June 10–12, 2002
NIH Consensus Statements are prepared by a nonadvocate, nonfederal panel of experts, based on (1) presentations by investigators working in areas relevant to the consensus questions during a 2-day public session, (2) questions and statements from conference attendees during open discussion periods that are part of the public session, and (3) closed deliberations by the panel during the remainder of the second day and morning of the third. This statement is an independent report of the panel and
Summary
The incidence of newly acquired hepatitis C infection has diminished in the United States. This decline is largely because of a decrease in cases among IDUs for reasons that are unclear and, to a lesser extent, to testing of blood donors for HCV. The virus is transmitted by blood, and such transmission now occurs primarily through injection drug use, sex with an infected partner or multiple partners, and occupational exposure. Most infections become chronic, and therefore the prevalence of HCV
Recommendations
- •
Educate the American public on the transmission of HCV in order to better identify affected individuals and to institute preventive measures.
- •
Develop reliable, reproducible, and efficient culture systems for propagating HCV and expand basic research in the pathogenic mechanisms underlying hepatic fibrosis.
- •
Promote the standardization and wide availability of diagnostic tests for HCV infection and its complications, leading to early diagnosis and the implementation of appropriate treatment
Consensus development panel
James L. Boyer, MD
Eugene B. Chang, MD
Deborah E. Collyar
Laurie D. DeLeve, MD, PhD
Judith Feinberg, MD
Thomas A. Judge, MD
Franco M. Muggia, MD
Charles L. Shapiro, MD
Stephen A. Spector, MD
Frederick J. Suchy, MD
Patricia L. Tomsko, MD, CMD
Barbara J. Turner, MD, MSEd
Speakers
Alfredo Alberti, MD
Miriam J. Alter, PhD
Bruce R. Bacon, MD
Gary L. Davis, MD
Adrian M. Di Bisceglie, MD
Jules L. Dienstag, MD
Brian R. Edlin, MD
Hashem B. El-Serag, MD, MPH
Michael W. Fried, MD
Kelly A. Gebo, MD, MPH
H. Franklin Herlong, MD
Jay H. Hoofnagle, MD
Maureen M. Jonas, MD
W. Ray Kim, MD, MSc, MBA
Karen L. Lindsay, MD
Anna S.F. Lok, MD
Patrick Marcellin, MD
John G. McHutchison, MD
Jean-Michel Pawlotsky, M, PhD
Marion G. Peters, MD, MBBS
Eve A. Roberts, MD, FRCPC
Leonard B. Seeff, MD
Mitchell L. Shiffman, MD
Planning committee
Leonard B. Seeff, MD
Miriam J. Alter, PhD
Luiz H. Barbosa, DVM
Eric B. Bass, MD, MPH
Jacqueline S. Besteman, JD, MA
John A. Bowersox
James L. Boyer, MD
Elsa A. Bray
John S. Cole III, PhD
Lawrence Deyton, MD, MSPH
Adrian M. Di Bisceglie, MD
Jules L. Dienstag, MD
Marguerite A. Evans, MS, RD
James Everhart, MD, MPH
Kelly A. Gebo, MD, MPH
Lt. Col. Roger Gibson, PhD, DVM, MPH
Jay H. Hoofnagle, MD
Leslye D. Johnson, PhD
Barnett S. Kramer, MD, MPH
Jake Liang, MD
Diane L. Lucas, PhD
Louis Marzella, MD, PhD
Karen Patrias, MLS
Conference sponsors
National Institute of Diabetes and Digestive and Kidney Diseases, Allen M. Spiegel, MD, Director
Office of Medical Applications of Research, Barnett S. Kramer, MD, MPH, Director
Conference cosponsors
National Institute of Child Health and Human Development, Duane Alexander, MD, Director
National Cancer Institute, Andrew C. von Eschenbach, MD
National Center for Complementary and Alternative Medicine, Stephen E. Straus, MD, Director
National Institute on Alcohol Abuse and Alcoholism, Raynard S. Kington, MD, PhD, Acting Director
National Institute on Drug Abuse, Glen R. Hanson, DDS, PhD, Acting Director
National Institute of Allergy and Infectious Diseases, Anthony S. Fauci, MD, Director
National
